About OEP

Founded in 1982, Orient EuroPharma Co., Ltd (OEP) was officially listed in the Gre-Tai Securities market in 2003, and consolidated net sales exceeded $5 billion in the 2014 financial year. Currently, OEP has more than 800 staffs worldwide, in which over 40% are overseas employees. OEP’s products include pharmaceuticals, cancer drugs, cosmeceutical, infant & adult nutrition and healthcare products. OEP also established a subsidiary company focused on developing and manufacturing new drugs. OEP is one of multinational pharmaceutical companies able to integrate pharmaceutical research & development, clinical trial, manufacture and marketing in Taiwan.

In 2013, OEP was named 2nd Benchmark Pharmaceutical Company in 2013 The Leading Biomedical Businesses of Taiwan by the Institute for Biotechnology and Medicine Industry. CommonWealth Magazine also placed OEP among the top 2000 large enterprises since 2012. In 2015, Listed as one of the top 100 businesses that the new generation most aspires to work for by Cheers: Happy Workers magazine.

OEP collaborated with multinational pharmaceutical companies to sell prescription drugs for five major treatments areas, including cardiovascular, cancer, central neuroscience system, respiratory, and hormones. For infant nutrition, OEP collaborated with New Zealand’s Dairy Goat Co-operatives (DGC) to market a new goat milk powder brand, Karihome. Karihome has successfully entered the China and Southeast Asia market, and is one of the few Taiwanese companies able to manage an international brand.

With the globalizing and growing market, OEP started to establish overseas subsidiaries in Singapore, Malaysia, Hong Kong and the Philippines since 1993. In 2006, OEP established the subsidiaries in Shanghai and Guangdong. In 2011, OEP expanded its market to Vietnam and planned to expand to Sri Lanka, Cambodia, Myanmar and India, strengthening OEP’s marketing and sales capability in the Asian Pacific region.

The subsidiary company OrientPHARMA Co., Ltd (OP) was founded in 2008 for developing and manufacturing new drugs. The OP plant is allocated in Huwei Park in Yunlin and has got the certifications of Taiwan PIC/S GMP, the “Accreditation Certification of Foreign Drug Manufacturer” from Japan MHLW, and US FDA international standards. Its progressive air-conditioning, water purification, air-compression and maintenance systems are capable of preventing plant and equipment cross contamination, and conform to international professional pharmaceutical standards for the next three decades.

In 2012, OEP expanded its R&D capabilities in the cancer drug area, and signed an agreement with Japan NanoCarrier Co., Ltd. to jointly develop new cancer drugs. In 2013, OPNano Co., Ltd was established, and the new injection plant began construction in 2014.

Company History
1982 Founded Orient EuroPharma Co., Ltd
1989 Imported infant goat formula from New Zealand, and created the Karihome brand for domestic sales in Taiwan
1999 Invested in the GMP pharmaceutical plant, gradually establishing subsidiaries in locations such as Singapore, Malaysia and Hong Kong

1.Purchased farms in New Zealand, becoming the first Taiwan goat milk supplier with approved membership in the New Zealand Dairy Board.
2. Established new offices in Philippines, further expanding the Company’s Southeast Asian territory.
3.Established the medical cosmetics department.


1.Officially listed for OTC trading.
2.Imported Swedish injectable hyaluronic acid products, becoming the first company in Taiwan to obtain government permit for brands with hyaluronic acid.


「Karihome」 series marketed in Hong Kong.


Established subsidiary company, OirentPHARMA Co., Ltd
「Karihome」 series marketed in Guangdong, China.


OirentPHARMA Co., Ltd approved as a biotechnology and pharmaceutical company by the Industrial Development Bureau, Ministry of Economic Affairs, and under biotechnology and pharmaceutical industry regulations, qualified for special research and development and training grants.


Established offices in Vietnam, enhancing Southeast Asian channels.


1.OirentPHARMA Co., Ltd awarded Taiwan’s Food and Drug Administration PIC/S GMP certification.
2. OirentPHARMA Co., Ltd approved and in effect for public listing


1.OirentPHARMA Co., Ltd awarded Japan’s official foreign pharmaceutical manufacturer certification.
2.OirentPHARMA Co., Ltd officially listed for OTC trading.
3.Signed agreement with Japan’s NanoCarrier Co., Ltd. to develop new pancreatic cancer drug and construct a new plant.


1. OirentPHARMA Co., Ltd awarded U.S. Food and Drug Administration Manufacturing Plant Inspection certification.
2. 「Karihome」cow series marketed in China


OP Nano Co,. Ltd was established, and the new injection plant began construction.